The relentless pursuit of efficiency, accuracy, and patient safety within the healthcare landscape has propelled automated dispensing cabinets (ADCs) to…
Read More
Eli Lilly is now pharma’s top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn’t celebrating
In a landmark announcement on April 1, the U.S. Food and Drug Administration (FDA) granted approval to Foundayo (orforglipron), Eli…
Read More
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical research and development stands at a pivotal juncture, experiencing a profound transformation that challenges long-held dichotomies in drug design.…
Read More
Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
Chinese researchers have unveiled a groundbreaking approach to treating ocular cancers, specifically retinoblastoma, through the development of specialized eye drops…
Read More
Sai Life Sciences’ Biotech Pitch Day 2026 Spotlights Emerging Innovation and Forges Crucial Collaborations in the Drug Discovery Landscape
Boston, MA – Sai Life Sciences, a leading global contract research, development, and manufacturing organization (CRDMO), recently convened its highly…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The burgeoning market for obesity treatments, propelled recently by the widespread adoption of GLP-1 receptor agonists, stands at a critical…
Read More
Immuto Scientific Pioneers AI-Enhanced Mass Spectrometry for Unprecedented Protein Structure Throughput
Immuto Scientific, a company co-founded in 2018 by CEO Faraz A. Choudhury, Ph.D., and CTO Daniel Benjamin, Ph.D., both electrical…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
The landscape of drug discovery and development is witnessing a significant resurgence in covalent inhibitors, a class of therapeutics that…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
The pharmaceutical industry, known for its dynamic shifts and competitive landscape, has witnessed a seismic change at its pinnacle. Eli…
Read MoreYOU MAY HAVE MISSED
